失智症药物市场：按药物类别、按适应症、按给药途径、按分销管道、按地区

失智症治疗市场预计到2024年将达到244.7亿美元，预计到2031年将达到383.3亿美元，2024年至2031年的复合年增长率为6.6%。

图：2024年失智症治疗药物的市场占有率（%），依地区划分

失智症治疗药物市场的成长是由全球阿兹海默症和其他失智症患者数量的增加所推动的。失智症是一种由影响大脑的疾病引起的综合征，例如阿兹海默症或中风。失智症的特征是思考、记忆和推理等认知功能逐渐丧失。由于人们对失智症诊断和治疗方法的认识不断提高，越来越多的人正在寻求针对失智症症症状的医疗协助。一些製药公司正在大力投资研究和开发有效药物，以减缓或阻止失智症的进展。

市场动态

失智症治疗市场的成长主要是由全球人口的快速老化所推动的，这增加了神经退化性疾病的风险。开发中国家不断增长的医疗保健支出和生物製药公司的密集研发工作进一步促进了市场扩张。然而，高昂的药物开发成本是一个重大挑战，特别是由于许多候选分子在后期临床试验中失败以及这些疾病的复杂性。最近核准的缓解疾病药物旨在影响疾病发病机制，而不是简单地缓解症状，这对製造商来说是一个重大机会。政府对失智症研究的支持和资助的增加正在鼓励市场参与企业创新和开发新的治疗方法。由于人口变化，失智症盛行率持续上升，对有效治疗方法的需求预计将增长，市场预计将取得重大进展。

本研究的主要特点

本报告对全球失智症治疗药物市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。

根据公司亮点、产品系列、关键绩效和策略等参数，对全球失智症药物市场的主要企业进行概况分析。

主要企业包括Biogen、 Eisai、Novartis、Cipla、H. Lundbeck、Otsuka Pharmaceutical、Sun Pharmaceutical Industries、Viatris、Mapipharma、AbbVie、Daiichi Sankyo、F. Hoffmann La Roche等将亮相。

该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球失智症治疗药物市场报告针对该行业的各个相关人员相关者，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

相关人员可以透过用于分析全球失智症治疗药物市场的各种策略矩阵来促进他们的决策。

目录

第一章 分析目的与前提

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特的分析
• 企业合併(M&A) 场景
• 流行病学
• 管道分析

第 4 章失智症药物市场：按药物类别划分，2019-2031 年（十亿美元）

• 单胺氧化酶抑制剂
• 胆碱酯酶抑制剂
• 麸胺酸抑制剂
• 其他的

第五章失智症药物市场：依适应症分类，2019-2031 年（十亿美元）

• 阿兹海默症失智症
• 路易氏体失智症
• 帕金森氏症失智症
• 其他的

第六章失智症药物市场：依给药途径划分，2019-2031 年（十亿美元）

• 口服
• 静脉
• 其他的

第七章失智症药物市场：依分销管道划分，2019-2031（十亿美元）

• 医院药房
• 零售药房
• 网路药房

第八章失智症药物市场：按地区划分，2019-2031 年（十亿美元）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第9章 竞争格局

• Biogen
• Eisai Co., Ltd.
• Novartis AG
• Cipla
• Lundbeck A/S
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Mapi-Pharma Ltd.
• AbbVie, Inc.
• DAIICHI SANKYO COMPANY, LIMITED.
• Hoffmann-La Roche Ltd

第10章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第十一章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Dementia drugs market is estimated to be valued at USD 24.47 Bn in 2024 and is expected to reach USD Bn 38.33 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

Figure. Dementia Drugs Market Share (%), By Region, 2024

Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.

Market Dynamics

Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.

Key features of the study

This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Market Segmentation

• By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitor
  • Others
• By Indication Insights (Revenue, USD Bn, 2019 - 2031)
  • Alzheimer's Disease Dementia
  • Lewy Body Dementia
  • Parkinson Disease Dementia
  • Others
• By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
  • Oral
  • Intravenous
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Biogen
  • Eisai Co., Ltd.
  • Novartis AG
  • Cipla
  • Lundbeck A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Mapi-Pharma Ltd.
  • AbbVie, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • F.Hoffmann-La Roche Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Dementia Drugs Market, By Drug Class
  • Dementia Drugs Market, By Indication
  • Dementia Drugs Market, By Route of Administration
  • Dementia Drugs Market, By Distribution Channel
  • Dementia Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology
• Pipeline Analysis

4. Dementia Drugs Market, By Drug Class, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• MAO Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cholinesterase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Glutamate Inhibitor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Dementia Drugs Market, By Indication, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Alzheimer's Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lewy Body Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Parkinson Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Dementia Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Dementia Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Dementia Drugs Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Pharmaceutical Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mapi-Pharma Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie, Inc.
• DAIICHI SANKYO COMPANY, LIMITED.
• Hoffmann-La Roche Ltd

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us